Canaccord initiated coverage of Tango Therapeutics (TNGX) with a Buy rating and $30 price target Tango is a precision oncology company with a “best-in-class” PRMT5 inhibitor for MTAP-deleted cancer, the analyst tells investors in a research note. The firm says combination studies with Revolution Medicines’ KRAS agents in pancreatic cancer put Tango “ahead of its competitors.” It expects positive data readouts in 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics initiated with a Buy at Canaccord
- Tango Therapeutics price target raised to $21 from $14 at B. Riley
- Tango Therapeutics price target raised to $20 from $19 at Mizuho
- Tango Therapeutics price target raised to $24 from $15 at Stifel
- Tango Therapeutics price target raised to $19 from $15 at Wedbush